SAN FRANCISCO--(BUSINESS WIRE)--Jul. 7, 2015--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, announced today that it has appointed Dr. Victoria Lewis as
Chief of Clinical Development. Dr. Lewis will oversee the planning,
strategic development, and operation of the Company’s expanding clinical
initiatives.
Dr. Lewis has spent 30 years in drug development, including 15 years
developing drugs in the animal health space. She began her career at
Novartis (Sandoz Inc.), followed by Serono Laboratories and Parexel
International Corporation. Upon receiving her doctorate in veterinary
medicine, Dr. Lewis joined Schering-Plough Animal Health (now Merck
Animal Health), where she held management positions as the company
evolved through its merger with Intervet and subsequent acquisition by
Merck. Most recently, she held a senior management position at
AlcheraBio, a contract research organization. Dr. Lewis' experience in
all phases of clinical trials, regulatory affairs and strategic planning
has led to the approval of multiple new animal drugs as well as expanded
label claims of previously approved products.
Dr. Lewis earned a B.S. in Pharmacy from the Massachusetts College of
Pharmacy and a doctorate in veterinary medicine from Tufts University
School of Veterinary Medicine.
“The addition of Dr. Lewis to our team comes at an exciting time for
Jaguar as we progress with the development of new and innovative
products for the companion and production animal markets. We have a
number of ongoing clinical programs, with more slated to begin in the
near-term,” stated Lisa Conte, Jaguar’s President and CEO. “Dr. Lewis’
breadth of industry and leadership experience will be a tremendous asset
to our team as we take further steps toward commercialization.”
“I am excited to join the Jaguar team and support the clinical
activities around the Company’s robust pipeline of gastrointestinal
products for companion and production animals worldwide. The Company is
uncompromising in its efforts to develop solutions for a number of
unaddressed gastrointestinal needs in the market. I look forward to
leveraging my industry knowledge with the team’s extensive background in
gastrointestinal and animal health to bring innovative prescription and
non-prescription products to a rapidly growing market,” commented Dr.
Lewis.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia™ is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of watery diarrhea in dogs. Neonorm™ Calf is the
Company’s lead non-prescription product. Canalevia is a canine-specific
formulation of crofelemer, an active pharmaceutical ingredient isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm is a standardized botanical extract derived from the Croton
lechleri tree. Canalevia and Neonorm are distinct products that act
at the same last step in a physiological pathway generally present in
mammals. Jaguar has filed nine Investigational New Animal Drug
applications, or INADs, with the FDA and intends to develop
species-specific formulations of Neonorm in six additional target
species, and formulations of Canalevia for cats, horses and dogs.
For more information, please visit www.jaguaranimalhealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150707005282/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Tram
Bui, 212-896-1290
tbui@kcsa.com
Jaguar-JAGX
